GeNeuro Announces Positive Results from Temelimab (GNbAC1) Phase 1 High-dose Clinical Trial
International Nonproprietary Name "temelimab" Assigned to GNbAC1
Temelimab’s robust safety and tolerability profile confirmed
High-dose regimen fully validated by pharmacokinetic data
Enables higher doses or front-loading to be considered for future clinical studies
Drug candidate’s overall profile enhanced ahead of a possible partnership to continue the global development of temelimab as a treatment for multiple sclerosis (MS)
International Nonproprietary Name "temelimab" assigned by the WHO for GNbAC1
Geneva, Switzerland, 21 January 2019 – 6.00pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, today announced positive safety and tolerability results from a Phase 1 study assessing the administration of high doses of temelimab (GNbAC1) to treat MS and other auto-immune diseases.